Costello, Christopher and Ward, Michael B. (2007): Search, bioprospecting, and biodiversity conservation. Published in: Journal of Environmental Economics and Management , Vol. 53, No. 2 (2007): pp. 158-179.
Download (302kB) | Preview
To what extent can private-sector bioprospecting incentives be relied upon for the protection of biological diversity? The literature contains dramatically different estimates of these incentives from trivial to quite large. We resolve this controversy by isolating the fundamental source of the discrepancy and then providing empirically defensible estimates based on that analysis. Results demonstrate that the bioprospecting incentive is unlikely to generate much private-sector conservation. Thus, other mechanisms are likely required to preserve the public good of biodiversity.
|Item Type:||MPRA Paper|
|Original Title:||Search, bioprospecting, and biodiversity conservation|
|Keywords:||Bioprospecting, biodiversity, conservation, efficient search, information|
|Subjects:||Q - Agricultural and Natural Resource Economics ; Environmental and Ecological Economics > Q5 - Environmental Economics > Q56 - Environment and Development ; Environment and Trade ; Sustainability ; Environmental Accounts and Accounting ; Environmental Equity ; Population Growth
Q - Agricultural and Natural Resource Economics ; Environmental and Ecological Economics > Q5 - Environmental Economics > Q57 - Ecological Economics: Ecosystem Services ; Biodiversity Conservation ; Bioeconomics ; Industrial Ecology
|Depositing User:||Michael B. Ward|
|Date Deposited:||09. Nov 2010 10:24|
|Last Modified:||01. Jan 2016 02:06|
Butler, M. (2004). The role of natural product chemistry in drug discovery. Journal of Natural Products 67 (12), 2141–2153.
Conservation International (2005). Conservation international biodiversity hotspots.
Cronquist, A. (1981). An Integrated System of Classification of Flowering Plants. New York: Columbia University Press.
Day-Rubenstein, K. and G. Frisvold (2001). Genetic prospecting and biodiversity development agreements. Land Use Policy 18, 205–219.
DiMasi, J., R. Hansen, and H. Grabowski (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics 22, 151–185.
DiMasi, J., R. Hansen, H. Grabowski, and L. Lasagna (1991). Cost of innovation in the pharma- ceutical industry. Journal of Health Economics 10, 107–142.
Fabricant, D. and N. Farnsworth (2001, March). The value of plants used in traditional medicine for drug discovery. Environmental Health Perspectives Supplements 109 (S1), 69–75.
Farnsworth, N. and D. Soejarto (1985). Potential consequence of plant extinction in the united states on the current and future availability of prescription drugs. Economic Bontany 39 (3), 231–240.
Firn, R. (2003). Bioprospecting – why is it so unrewarding. Biodiversity and Conservation 12, 207–216.
Grabowski, H. and J. Vernon (2000). The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 (Suppl. 1), 21–32.
INBio (2005). Products generate resources for conservation. Press Release.
Kassar, I. and P. Lasserre (2004). Species preservation and biodiversity value: a real options approach. Journal of Environmental Economics and Management 48 (2), 857–879.
Keeley, J. and C. Fotheringham (2003). Species-area relationships in Mediterranean-climate plant communities. Journal of Biogeography 30, 1629–1657.
Kilburn, P. (1966). Analysis of the species-area relation. Ecology 47 (5), 831–843.
Koo, B. and B. Wright (1999). The role of biodiversity products as incentives for conserving biological diversity: some instructive examples. The Science of the Total Environment 240, 21–30.
Myers, N. (1988). Threatened biotas: hot spots in tropical forests. Environmentalist 10 (3), 187– 208.
Myers, N. (1990). The biodiversity challenge: expanded hot-spots analysis. Environmental- ist 10 (4), 243–256.
Myers, N., R. Mittermeier, C. Mittermeier, G. da Fonseca, and J. Kent (2000). Biodiversity hotspots for conservation priorities. Nature 403, 853–858.
Nigh, R. (2002). Maya medicine in the biological gaze. Current Anthropology 43 (3), 451–477. Onaga (2002, May). Cashing on in nature’s pharmacy. EMBO Reports.
Polasky, S. and A. Solow (1995). On the value of a collection of species. Journal of Environmental Economics and Management 29 (3), 298–303.
Polasky, S., A. Solow, and J. Broadus (1993). Searching for uncertain benefits and the conservation of biological diversity. Environmental and Resource Economics 3, 171–181.
Preston, F. (1960). Time and space and the variation of species. Ecology 41, 611–627.
Proudfoot, J. (2002). Drugs, leads, and drug-likeness: An analysis of some recently launched drugs. Bioorganic and Medicinal Chemistry Letters 12, 1647–1650.
Rausser, G. and A. Small (2000). Valuing research leads: bioprospecting and the conservation of genetic resources. Journal of Political Economy 108 (1), 173–206.
Shackleton, C. (2001). Re-examining local and market-oriented use of wild species for the conser- vation of biodiversity. Environmental Conservation 28 (3), 270–278.
Simpson, D., R. Sedjo, and J. Reid (1996). Valuing biodiversity for use in pharmaceutical research. Journal of Political Economy 104 (1), 163–185.
South Asian Network for Development and Environmental Economics (2003, February). Sandee newsletter #6.
Weitzman, M. (2001). Gamma discounting. The American Economic Review 91 (1), 260–271.
Weitzman, M. L. (1979). Optimal search for the best alternative. Econometrica 47 (3), 641–654.